Medical Innovation

Equal Costs, Unequal Risk: BBH’s Concentration Versus XPH’s Breadth

A 25‑stock biotech fund that leans heavily on a few large names shows higher volatility and split returns while a 65‑stock pharmaceuticals ETF delivers broader, steadier exposure.